2024 |
Duszyk K, Marie McDonald V, Thomas D, Steel K, Gerard Gibson P, 'The treatable traits of asthma in pregnancy: a clinical audit', ERJ Open Research, 00748-2023
|
|
|
2024 |
Thomas D, McDonald VM, Stevens S, Baraket M, Hodge S, James A, et al., 'Azithromycin Induced Asthma Remission in Adults With Persistent Uncontrolled Asthma: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial.', Chest, (2024) [C1]
|
|
|
2024 |
Thomas D, McDonald VM, Stevens S, Harvey ES, Baraket M, Bardin P, et al., 'Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients.', Allergy, 79 384-392 (2024) [C1]
|
|
Nova |
2023 |
Kritikos V, Harvey ES, Stevens S, Katelaris CH, Langton D, Rimmer J, et al., 'Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma.', J Allergy Clin Immunol Pract, 11 885-895.e13 (2023) [C1]
|
|
Nova |
2023 |
Gibson PG, McDonald VM, Thomas D, 'Treatable traits, combination inhaler therapy and the future of asthma management', Respirology, 28 828-840 (2023) [C1]
|
|
Nova |
2023 |
Cross AJ, Geethadevi GM, Magin P, Baker AL, Bonevski B, Godbee K, et al., 'A novel, multidomain, primary care nurse-led and mHealth-assisted intervention for dementia risk reduction in middle-aged adults (HAPPI MIND): study protocol for a cluster randomised controlled trial', BMJ OPEN, 13 (2023)
|
|
|
2023 |
Gobarani RK, Weeks GR, Abramson MJ, Bonevski B, Paul E, Webb A, et al., 'Which smokers enroll in a hospital based smoking cessation trial? Survey of smoking related behaviors, quit attempts, and motivation to quit.', Health promotion journal of Australia : official journal of Australian Association of Health Promotion Professionals, 34 420-428 (2023) [C1]
|
|
Nova |
2022 |
Thomas D, Gibson PG, 'Long-Term, Low-Dose Azithromycin for Uncontrolled Asthma in Children', CHEST, 162 27-29 (2022)
|
|
|
2022 |
Thomas D, McDonald VM, Pavord ID, Gibson PG, 'Asthma remission: what is it and how can it be achieved?', EUROPEAN RESPIRATORY JOURNAL, 60 (2022) [C1]
|
|
Nova |
2022 |
Thomas D, McDonald VM, Simpson JL, Smith A, Gupta S, Majellano E, Gibson PG, 'Patterns of azithromycin use in obstructive airway diseases: a real-world observational study.', Intern Med J, 52 1016-1023 (2022) [C1]
|
|
Nova |
2022 |
Cross AJ, Liang J, Thomas D, Zairina E, Abramson MJ, George J, 'Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary care (Review)', COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (2022) [C1]
|
|
Nova |
2022 |
Thomas D, Gibson PG, 'Gefapixant for chronic cough', LANCET, 399 886-887 (2022)
|
|
|
2021 |
Thomas D, Harvey ES, McDonald VM, Stevens S, Upham JW, Katelaris CH, et al., 'Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry', Journal of Allergy and Clinical Immunology: In Practice, 9 2715-2724.e5 (2021) [C1]
|
|
Nova |
2021 |
Tobaiqy M, Thomas D, MacLure A, Stewart D, MacLure K, 'Staff and student experiences and attitudes towards smoking and smoking cessation, University of Jeddah, Saudi Arabia', Tobacco Prevention and Cessation, 7 (2021) [C1]
|
|
Nova |
2021 |
Courtney RJ, McRobbie H, Tutka P, Weaver NA, Petrie D, Mendelsohn CP, et al., 'Effect of Cytisine vs Varenicline on Smoking Cessation A Randomized Clinical Trial', JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 326 56-64 (2021) [C1]
|
|
Nova |
2021 |
Tobaiqy M, MacLure A, Thomas D, MacLure K, 'The Impact of COVID-19 on Smoking Behaviours and Support for Smoke-Free Zones in Saudi Arabia', INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 18 (2021) [C1]
|
|
Nova |
2020 |
Tobaiqy M, Thomas D, MacLure A, MacLure K, 'Smokers' and Non-Smokers' Attitudes towards Smoking Cessation in Saudi Arabia: A Systematic Review', INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 17 (2020) [C1]
|
|
Nova |
2020 |
Gobarani RK, Abramson MJ, Bonevski B, Weeks GR, Dooley MJ, Smith BJ, et al., 'The efficacy and safety of varenicline alone versus in combination with nicotine lozenges for smoking cessation among hospitalised smokers (VANISH): study protocol for a randomised, placebo-controlled trial', BMJ OPEN, 10 (2020)
|
|
|
2020 |
Lappin JM, Thomas D, Curtis J, Blowfield S, Gatsi M, Marr G, Courtney R, 'Targeted Intervention to Reduce Smoking among People with Severe Mental Illness: Implementation of a Smoking Cessation Intervention in an Inpatient Mental Health Setting', Medicina, 56 (2020) [C1]
|
|
|
2019 |
Thomas D, Farrell M, McRobbie H, Tutka P, Petrie D, West R, et al., 'The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial', ADDICTION, 114 923-933 (2019)
|
|
|
2019 |
Chui CY, Taylor SE, Thomas D, George J, 'Prevalence and recognition of highly significant medication-smoking cessation interactions in a smoke-free hospital', Drug and Alcohol Dependence, 200 78-81 (2019)
Background: Some medications are more rapidly metabolized by smokers; upon smoking cessation, medication metabolism may be significantly reduced, resulting in medication-related a... [more]
Background: Some medications are more rapidly metabolized by smokers; upon smoking cessation, medication metabolism may be significantly reduced, resulting in medication-related adverse events. Clozapine, olanzapine and theophylline have been deemed to have potentially highly significant interactions with smoking cessation, which could lead to seizures, extrapyramidal effects and tachycardia, respectively. This study examined the period prevalence and characteristics of patients at risk of highly significant medication-smoking cessation interactions when admitted to a smoke-free hospital. Methods: A retrospective cross-sectional study was undertaken in an Australian tertiary-referral hospital with a well-established electronic prescribing system. Smokers prescribed clozapine, olanzapine or theophylline prior to and during a hospital admission in 2015 were included. Length of hospital stay, daily doses, and recognition of the potential interaction by treating clinicians were determined from medical records. Results: The period prevalence of patients at risk of a potentially highly significant medication-smoking cessation interaction was 23/48 (48%), 66/256 (26%) and 1/16 (6%) amongst smokers prescribed clozapine, olanzapine or theophylline, respectively. These interactions were poorly recognized by healthcare professionals during the admission. Conclusions: Up to one in two patients receiving medications that have potentially highly significant interactions with smoking cessation may be experiencing clinically significant potential interactions. Such interactions, however, were commonly overlooked by hospital staff. Interventions to improve awareness of this issue are warranted.
|
|
|
2018 |
George J, Thomas D, 'E-cigarettes for harm minimisation: absence of evidence or evidence of absence?', International Journal of Pharmacy Practice, 26 377-379 (2018)
|
|
|
2018 |
Chui CY, Thomas D, Taylor S, Bonevski B, Abramson MJ, Paul E, et al., 'Factors associated with nicotine replacement therapy use among hospitalised smokers.', Drug and alcohol review, 37 514-519 (2018) [C1]
|
|
Nova |
2017 |
Thomas D, Abramson MJ, Bonevski B, George J, 'System change interventions for smoking cessation', Cochrane Database of Systematic Reviews, 1-40 (2017) [C1]
|
|
Nova |
2016 |
Thomas D, Mackinnon AJ, Bonevski B, Abramson MJ, Taylor S, Poole SG, et al., 'Development and validation of a 21-item challenges to stopping smoking (CSS-21) scale', BMJ Open, 6 (2016) [C1]
Objective: Identification of challenges associated with quitting and overcoming them may improve cessation outcomes. This study describes the development and initial validation of... [more]
Objective: Identification of challenges associated with quitting and overcoming them may improve cessation outcomes. This study describes the development and initial validation of a scale for measuring challenges to stopping smoking. Methods: The item pool was generated from empirical and theoretical literature and existing scales, expert opinion and interviews with smokers and ex-smokers. The questionnaire was administered to smokers and recent quitters who participated in a hospital-based smoking cessation trial. Exploratory factor analysis was performed to identify subscales in the questionnaire. Internal consistency, validity and robustness of the subscales were evaluated. Results: Of a total of 182 participants with a mean age of 55 years (SD 12.8), 128 (70.3%) were current smokers and 54 (29.7%) ex-smokers. Factor analysis of the 21-item questionnaire resulted in a 2-factor solution representing items measuring intrinsic (9 items) and extrinsic (12 items) challenges. This structure was stable in various analyses and the 2 factors accounted for 50.7% of the total variance of the polychoric correlations between the items. Internal consistency (Cronbach's a) coefficients for the intrinsic and extrinsic subscales were 0.86 and 0.82, respectively. Compared with ex-smokers, current smokers had a higher mean score (±SD) for intrinsic (24.0±6.4 vs 20.5±7.4, p=0.002) and extrinsic subscales (22.3±7.5 vs 18.6±6.0, p=0.001). Conclusions: Initial evaluation suggests that the 21-item challenges to stopping smoking scale is a valid and reliable instrument that can be used in research and clinical settings to assess challenges to stopping smoking.
|
|
Nova |
2016 |
Thomas D, Abramson MJ, Bonevski B, Taylor S, Poole SG, Paul E, et al., 'Integrating smoking cessation into routine care in hospitals-a randomized controlled trial', Addiction, 111 714-723 (2016) [C1]
Aims: To evaluate the effectiveness of a pharmacist-led multi-component smoking cessation programme (GIVE UP FOR GOOD) compared with usual care in hospitalized smokers. Design: Ra... [more]
Aims: To evaluate the effectiveness of a pharmacist-led multi-component smoking cessation programme (GIVE UP FOR GOOD) compared with usual care in hospitalized smokers. Design: Randomized, assessor-blinded, parallel-group trial. Setting: Three tertiary public hospitals in Australia. Participants: A total of 600 adult in-patient smokers [mean ± standard deviation (SD), age 51 ± 14 years; 64% male] available for 12 months follow-up. Interventions: Multi-component hospital pharmacist-led behavioural counselling and/or pharmacotherapy provided during hospital stay, on discharge and 1 month post-discharge, with further support involving community health professionals (n = 300). Usual care comprised routine care provided by hospitals (n = 300). Measurements: Two primary end-points were tested using intention-to-treat analysis: carbon monoxide (CO)-validated 1-month sustained abstinence at 6-month follow-up and verified 6-month sustained abstinence at 12-month follow-up. Smoking status and pharmacotherapy usage were assessed at baseline, discharge, 1, 6 and 12 months. Findings: Sustained abstinence rates for intervention and control groups were not significantly different at both 6 months [11.6% (34 of 294) versus 12.6% (37 of 294); odds ratio (OR) = 0.91, 95% confidence interval (CI) = 0.55-1.50] and 12 months [11.6% (34 of 292) versus 11.2% (33 of 294); OR = 1.04, 95% CI = 0.63-1.73]. Secondary end-points, self-reported continuous abstinence at 6 and 12 months, also agreed with the primary end-points. Use of pharmacotherapy was higher in the intervention group, both during hospital stay [52.3% (157 of 300) versus 42.7% (128 of 300); P = 0.016] and after discharge [59.6% (174 of 292) versus 43.5% (128 of 294); P < 0.001]. Conclusions: A pharmacist-led multi-component smoking cessation intervention provided during hospital stay did not improve sustained abstinence rates at either 6 or 12 months compared with routine hospital care.
|
|
Nova |
2015 |
Tan ECK, Jokanovic N, Koponen MPH, Thomas D, Hilmer SN, Bell JS, 'Prevalence of analgesic use and pain in people with and without dementia or cognitive impairment in aged care facilities: A systematic review and meta-analysis', Current Clinical Pharmacology, 10 194-203 (2015)
Pain is a frequent cause of discomfort and distress in residents in residential aged care facilities (RACFs). Despite the benefits of adequate pain management, there is inconsiste... [more]
Pain is a frequent cause of discomfort and distress in residents in residential aged care facilities (RACFs). Despite the benefits of adequate pain management, there is inconsistency in the literature regarding analgesic use and pain in residents with dementia. The aim of this systematic review was to determine the prevalence of analgesic drug use among residents with and without dementia or cognitive impairment in RACFs. A systematic search of MEDLINE and EMBASE (inception to January 2014) was conducted using Medical Subject Headings and Emtree terms, respectively. Studies were included if they reported prevalence of analgesic use for residents both with and without dementia within the same study. Data extraction and quality assessment was performed independently by two investigators. Data on the prevalence of analgesic use, pain and painful conditions were extracted. Meta-analyses were performed using random effect models. The 7 included studies were of high quality (=5 out of 7 on the adapted Newcastle-Ottawa Scale). Analgesic use in residents with and without dementia or cognitive impairment ranged from 20.2% to 61.2% and 38.8% to 79.6%, respectively. Paracetamol was the most prevalent analgesic in people with and without dementia. Residents with dementia or cognitive impairment had a significantly lower prevalence of analgesic use (odds ratio [OR] 0.576, 95% confidence interval [CI] = 0.406-0.816) and of self-reported and clinician-observed pain (OR 0.355, 95% CI = 0.278-0.454) than residents without cognitive impairment, despite a comparable prevalence of painful conditions. These findings may indicate under-reporting and under-detection of pain in persons with dementia, and subsequent suboptimal treatment.
|
|
|
2015 |
Thomas D, Abramson MJ, Bonevski B, Taylor S, Poole SG, Weeks GR, et al., 'Quitting experiences and preferences for a future quit attempt: A study among inpatient smokers', BMJ Open, 5 (2015) [C1]
Objective: Understanding smokers' quit experiences and their preferences for a future quit attempt may aid in the development of effective cessation treatments. The aims of t... [more]
Objective: Understanding smokers' quit experiences and their preferences for a future quit attempt may aid in the development of effective cessation treatments. The aims of this study were to measure tobacco use behaviour; previous quit attempts and outcomes; methods used to assist quitting; difficulties experienced during previous attempts; the motives and preferred methods to assist quitting in a future attempt; identify the factors associated with preferences for smoking cessation. Design: Face-to-face interview using a structured questionnaire. Setting: Inpatient wards of three Australian public hospitals. Participants: Hospitalised smokers enrolled in a smoking cessation trial. Results: Of 600 enrolled patients (42.8% participation rate), 64.3% (n=386) had attempted quitting in the previous 12 months. On a scale of 1 (low) to 10 (high), current motivation to quit smoking was high (median 9; IQR 6.5-10), but confidence was modest (median 5; IQR 3-8). Among 386 participants who reported past quit attempts, 69.9% (n=270) had used at least one cessation aid to assist quitting. Nicotine replacement therapy (NRT) was most commonly stated (222, 57.5%), although the majority had used NRT for <4 weeks. Hypnotherapy was the most common (68, 17.6%) non-pharmacological treatment. Over 80% (n=311) experienced withdrawal symptoms; craving and irritability were commonly reported. Most participants (351, 58.5%) believed medications, especially NRT (322, 53.7%), would assist them to quit in the future. History of previous smoking cessation medication use was the only independent predictor of interest in using medications for a future quit attempt. Conclusions: The majority of smokers had attempted quitting in the previous 12 months; NRT was a popular cessation treatment, although it was not used as recommended by most. This suggests a need for assistance in the selection and optimal use of cessation aids for hospitalised smokers. Trial registration number: Australian and New Zealand Clinical Trials Registry: ACTRN12612000368831.
|
|
Nova |
2014 |
George J, Thomas D, 'Tackling tobacco smoking: Opportunities for pharmacists', International Journal of Pharmacy Practice, 22 103-104 (2014)
|
|
|
2013 |
Thomas D, Abramson MJ, Bonevski B, George J, 'System change interventions for smoking cessation', Cochrane Database of Systematic Reviews, 2013 (2013)
This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effectiveness of system change interventions within healthcare settings, f... [more]
This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effectiveness of system change interventions within healthcare settings, for increasing smoking cessation.
|
|
|
2013 |
Thomas D, Abramson MJ, Bonevski B, Taylor S, Poole S, Weeks GR, et al., 'A pharmacist-led system-change smoking cessation intervention for smokers admitted to Australian public hospitals (GIVE UP FOR GOOD): study protocol for a randomised controlled trial', TRIALS, 14 (2013) [C3]
|
|
Nova |
2011 |
Jerajani HR, Kumar AS, Kuruvila M, Nataraja HV, Philip M, Pratap DVS, et al., 'Efficacy and safety of topical halometasone in eczematous dermatoses in Indian population: An open label, noncomparative study', Indian Journal of Dermatology, 56 652-656 (2011)
Background: Topical steroids remain the mainstay of treatment in eczema, an inflammatory skin reaction characterized by pruritus, redness, scaling, and clustered oozing papulovesi... [more]
Background: Topical steroids remain the mainstay of treatment in eczema, an inflammatory skin reaction characterized by pruritus, redness, scaling, and clustered oozing papulovesicles. Halometasone is a new potent corticosteroid approved in the Indian market for topical application in the treatment of dermatitis. Aims: To evaluate the efficacy and safety of halometasone in the treatment of acute or chronic noninfected eczematous dermatosis in Indian population. Materials and Methods: A prospective, open, multicentric, phase 3, noncomparative clinical trial conducted at outpatient departments of seven centres. Two hundred endogenous eczema patients meeting study criteria were enrolled. Halometasone 0.05% cream was applied twice daily for 30 days in chronic and 20 days in acute eczema patients. Calculation of eczema area and severity index, and assessment of investigator's global assessment of severity of eczema and severity of pruritus score were done at each visit and compared with baseline. All adverse events (AE) were captured and documented. Laboratory investigations including haematological tests, urinalysis, renal and liver function tests were performed at baseline and at end of treatment. Results: Of the 200 patients enrolled, 180 were chronic and 20 were acute eczema patients. It was found that there was a significant (P<0.001) improvement in all efficacy parameters compared with baseline. The treatment was shown to be successful in 91% patients. AE were reported in 30 patients and there was no serious AE reported. There was no clinically significant difference in laboratory investigations with treatment. Conclusions: Halometasone was shown to be safe and very effective in Indian patients with acute and chronic eczema and the drug was well tolerated.
|
|
|
2011 |
Thomas D, Meera NK, Binny K, Sekhar MS, Kishore G, Sasidharan S, 'Medication adherence and associated barriers in hypertension management in India', Global Heart, 6 9-9
|
|
|
2011 |
Latha MS, Paul AD, Krishnankutty B, Thomas G, Thomas D, 'Evaluation of Amlodipine besylate in the treatment of isolated Systolic hypertension in Indian patients', Asian Journal of Pharmaceutical and Clinical Research, 4 80-82 (2011)
Aim: The aim of the study was to evaluate tolerability and benefits of Amlodipine besylate in adult Indians with Isolated Systolic Hypertension. Methods: This was a phase IV, mult... [more]
Aim: The aim of the study was to evaluate tolerability and benefits of Amlodipine besylate in adult Indians with Isolated Systolic Hypertension. Methods: This was a phase IV, multicentric, open labeled, prospective study conducted in the outpatient setup. Eligible patients who gave written informed consent, were treated with Amlodipine besylate (2.5-10mg/day) and evaluated frequently till the treatment goals were achieved (SBP < 140 mm Hg). Results: Of 1770 patients who received Amlodipine besylate, 93.88% achieved the desired therapeutic response. 24.01% of patients responded to the treatment within 14 days. There was a significant association between the grades of ISH and initial dose prescribed, with grade III patients requiring higher dose. There was an association between the previously untreated and inadequately treated groups and the initial dose of Amlodipine besylate (p=0.00), with higher dose being prescribed to the latter group. The drug was well tolerated. Conclusion:Amlodipine besylate is an effective, well tolerated antihypertensive agent in adult Indian patients with isolated systolic hypertension and exhibits a good safety profile.
|
|
|
2010 |
Advani SH, Achreckar S, Thomas D, Krishnankutty B, 'Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia', Indian Journal of Medical and Paediatric Oncology, 31 125-128 (2010)
Background: The use of granulocyte colony-stimulating factors to treat patients with chemotherapy-induced neutropenia is well accepted. To assess whether administration of filgras... [more]
Background: The use of granulocyte colony-stimulating factors to treat patients with chemotherapy-induced neutropenia is well accepted. To assess whether administration of filgrastim along with standard empiric antibiotic therapy is beneficial for patients with chemotherapy-induced febrile neutropenia (FN), we conducted an open, non-randomized clinical trial. Materials and Methods: This was a prospective, open, Phase IV clinical trial in patients receiving chemotherapy for histologically confirmed cancer, with an oral temperature of >38.2C and absolute neutrophil count (ANC) of <500/mm 3. Filgrastim was administered subcutaneously in a dose of 5 mcg/kg/day, 24 hours after administration of cytotoxic therapy, for up to two weeks or until the ANC reached 10,000 cells/mm 3. The parameters of assessment included duration of neutropenia, fever, hospitalization and antibiotic usage. Results: All 24 evaluable patients recovered from neutropenia, fever and FN in a median duration of two days. This result is similar to that reported in earlier studies with filgrastim. Despite the acceleration in recovery from neutropenia and fever, it also reduced the duration of hospital stay and usage of intravenous (IV) antibiotic. Only two adverse events were reported, which were of mild nature. Conclusion: Filgrastim, when used in patients with chemotherapy-induced neutropenia, exhibited efficacy in accelerating the recovery from neutropenia and fever comparable to that reported with filgrastim in literature. The data from this study suggest that filgrastim is effective in the treatment of chemotherapy-induced neutropenia and is well tolerated by Indian patients.
|
|
|